Lead Product(s): Cladribine
Therapeutic Area: Neurology Product Name: CRD1
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Omega Funds
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 13, 2020
The financing will allow the company to progress CRD1 through Phase 2 proof of concept clinical development. The potential of CRD1 to address unmet medical needs in rare autoimmune disorders was identified by Chord Therapeutics‘ founder, Dr. Arthur Roach.